Synergistic effect of a tissue kallikrein 1 and tissue inhibitor of matrix metalloproteinase 1 co‑expression vector on the proliferation of rat vascular smooth muscle cells

Zhu,Pengli; Yu,Huizhen; Huang,Shujie; Xiang,Hong; Li,Feng; Zheng,Weiping

doi:10.3892/mmr.2015.4198

Synergistic effect of a tissue kallikrein 1 and tissue inhibitor of matrix metalloproteinase 1 co‑expression vector on the proliferation of rat vascular smooth muscle cells

Authors:
- Pengli Zhu
- Huizhen Yu
- Shujie Huang
- Hong Xiang
- Feng Li
- Weiping Zheng
View Affiliations

Affiliations: Department of Geriatrics, Fujian Provincial Hospital Key Laboratory of Geriatrics, Fujian Medical University, Fuzhou, Fujian 350001, P.R. China, Department of Cardiology, Fujian Provincial Hospital, Fuzhou, Fujian 350001, P.R. China
Published online on: August 7, 2015 https://doi.org/10.3892/mmr.2015.4198
Pages: 5671-5678
Copyright: © Zhu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tissue kallikrein 1 (TK1) and tissue inhibitor of matrix metalloproteinase 1 (TIMP1) are important in inhibiting vascular smooth muscle cell (VSMC) proliferation and improving vascular remodeling, respectively. It was hypothesized that a combination of TK1 and TIMP1 genes, mediated by an adenovirus vector could augment or act in synergy to enhance the inhibitory effects. The promoter, mCMV carrying hTIMP1 cDNA was subcloned into pDC316‑hTK1 to construct a recombinant plasmid carrying hTK1 and hTIMP1 genes. Subsequently, the double gene plasmid and adenovirus backbone plasmid were packaged into HEK293A cells. Gene transcription and protein expression were examined, respectively using reverse transcription‑quantitative polymerase chain reaction (PCR) and western blotting assays. VSMC proliferation was assessed using cell counting and methyl‑thiazolyl‑tetrazoliuin methods. The constructed plasmid containing hTK1 and hTIMP1 genes was correctly identified by means of PCR, double digestion and sequencing analysis. The co‑expression vector, Ad‑hTK1‑hTIMP1 was successfully constructed and packaged into HEK293A cells. When VSMCs were transfected with the co‑expression vector, the mRNA transcription and protein expression of hTK1 and hTIMP1 exhibited abundant expression in a concentration‑dependent and time‑dependent manner, independently. In conclusion, the co‑expression vector synergistically inhibited the cell growth and proliferation induced by platelet‑derived growth factor‑BB compared with the single gene vector.

View Figures

View References

1	Ashley PL and MacDonald RJ: Tissue-specific expression of kallikrein-related genes in the rat. Biochemistry. 24:4520–4527. 1985. View Article : Google Scholar : PubMed/NCBI
2	Gerald WL, Chao J and Chao L: Sex dimorphism and hormonal regulation of rat tissue kallikrein mRNA. Biochim Biophys Acta. 867:16–23. 1986. View Article : Google Scholar : PubMed/NCBI
3	Yao Y, Sheng Z, Li Y, Yan F, Fu C, Li Y, Ma G, Liu N, Chao J and Chao L: Tissue kallikrein promotes cardiac neovascularization by enhancing endothelial progenitor cell functional capacity. Hum Gene Ther. 23:859–870. 2012. View Article : Google Scholar : PubMed/NCBI
4	Yin H, Chao L and Chao J: Nitric oxide mediates cardiac protection of tissue kallikrein by reducing inflammation and ventricular remodeling after myocardial ishchemia/reperfusion. Life Sci. 82:156–165. 2008. View Article : Google Scholar
5	Liu Y, Bledsoe G, Hagiwara M, Yang ZR, Shen B, Chao L and Chao J: Blockade of endogenous tissue kallikrein aggravates renal injury by enhancing oxidative stress and inhibiting matrix degradation. Am J Physiol Renal Physiol. 298:F1033–F1040. 2010. View Article : Google Scholar : PubMed/NCBI
6	Lan W, Yang F, Liu L, Yin Q, Li M, Li Z, Sang H, Xu G, Ma M, Zhang Z, et al: Tissue kallikrein preventing the restenosis after stenting of symptomatic MCA atherosclerotic stenosis (KPRASS). Int J Stroke. 9:533–535. 2014. View Article : Google Scholar
7	Yu HZ, Xie LD, Zhu PL, Xu CS and Wang HJ: Human tissue kallikrein 1 gene delivery inhibits PDGF-BB-induced vascular smooth muscle cells proliferationand upregulates the expressions of p27Kip1 and p2lCip1. Mol Cell Biochem. 360:363–371. 2012. View Article : Google Scholar
8	Yu HZ, Xie LD, Zhu PL, Xu CS, Wang HJ and Li TY: Effects of human tissue kallikrein 1 gene delivery on carotid artery neointima formation after balloon angioplasty in spontaneously hypertensive rats. Zhonghua Xin Xue Guan Bing Za Zhi. 38:67–71. 2010.In Chinese. PubMed/NCBI
9	Heagerty AM, Heerkens EH and Izzard AS: Small artery structure and function in hypertension. J Cell Mol Med. 14:1037–1043. 2010.PubMed/NCBI
10	Intengan HD and Schiffrin EL: Vascular remodeling in hypertension: Roles of apoptosis, inflammation and fibrosis. Hypertension. 38:581–587. 2001. View Article : Google Scholar : PubMed/NCBI
11	Zitka O, Kukacka J, Krizkova S, Huska D, Adam V, Masarik M, Prusa R and Kizek R: Matrix metalloproteinases. Curr Med Chem. 17:3751–3768. 2010. View Article : Google Scholar : PubMed/NCBI
12	Papazafiropoulou A and Tentolouris N: Matrix metalloproteinases and cardiovascular diseases. Hippokratia. 13:76–82. 2009.PubMed/NCBI
13	Docherty AJ, Lyons A, Smith BJ, Wright EM, Stephens PE, Harris TJ, Murphy G and Reynolds JJ: Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature. 318:66–69. 1985. View Article : Google Scholar : PubMed/NCBI
14	Dollery CM, Humphries ES, McClelland A, Latchman DS and McEwan JR: Expression of tissue inhibitor of matrix metal-loproteinases 1 by use of an adenoviral vector inhibits smooth muscle cell migration and reduces neointimal hyperplasia in the rat model of vascular balloon injury. Circulation. 99:3199–3205. 1999. View Article : Google Scholar : PubMed/NCBI
15	Pei Z, Chu L, Zou W, Zhang Z, Qiu S, Qi R, Gu J, Qian C and Liu X: An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice. Hepatology. 39:1371–1381. 2004. View Article : Google Scholar : PubMed/NCBI
16	Shen Y, Muramatsu SI, Ikeguchi K, Fujimoto KI, Fan DS, Ogawa M, Mizukami H, Urabe M, Kume A, Nagatsu I, et al: Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase and GTP cyclohydrolase I for gene therapy of Parkinson's disease. Hum Gene Ther. 11:1509–1519. 2000. View Article : Google Scholar : PubMed/NCBI
17	Ngoi SM, Chien AC and Lee CG: Exploiting internal ribosome entry sites in gene therapy vector design. Curr Gene Ther. 4:15–31. 2004. View Article : Google Scholar : PubMed/NCBI
18	Denes L, Entz L and Jancsik V: Restenosis and therapy. Int J Vasc Med. 4062362012.PubMed/NCBI
19	Ng P, Parks RJ, Cummings DT, Evelegh CM, Sankar U and Graham FL: A high-efficiency Cre/loxP-based system for construction of adenoviral vectors. Hum Gene Ther. 10:2667–2672. 1999. View Article : Google Scholar : PubMed/NCBI
20	Maeda M, Namikawa K, Kobayashi I, Ohba N, Takahara Y, Kadono C, Tanaka A and Kiyama H: Targeted gene therapy toward astrocytoma using a Cre/loxP-based adenovirus system. Brain Res. 1081:34–43. 2006. View Article : Google Scholar : PubMed/NCBI
21	Chen HF, Xie LD and Xu CS: The signal transduction pathways of heat shock protein 27 phosphorylation in vascular smooth muscle cells. Mol Cell Biochem. 333:49–56. 2010. View Article : Google Scholar
22	Gariepy J, Massonneau M, Levenson J, Heudes D and Simon A: Evidence for in vivo carotid and femoral wall thickening in human hypertension. Groupe de Prévention Cardio-vasculaire en Médecine du Travail. Hypertension. 22:111–118. 1993. View Article : Google Scholar : PubMed/NCBI
23	Wilson DR: Viral-mediated gene transfer for cancer treatment. Curr Pharm Biotechnol. 3:151–164. 2002. View Article : Google Scholar : PubMed/NCBI
24	Eefting D, Seghers L, Grimbergen JM, de Vries MR, de Boer HC, Lardenoye JW, Jukema JW, van Bockel JH and Quax PH: A novel urokinase receptor-targeted inhibitor for plasmin and matrix metalloproteinases suppresses vein graft disease. Cardiovasc Res. 88:367–375. 2010. View Article : Google Scholar : PubMed/NCBI
25	Jiang M, Shi W, Zhang Q, Wang X, Guo M, Cui Z, Su C, Yang Q, Li Y, Sham J, et al: Gene therapy using adenovirus-mediated full-length anti-HER-2 antibody for HER-2 overexpression cancers. Clin Cancer Res. 12:6179–6185. 2006. View Article : Google Scholar : PubMed/NCBI
26	Guo SY, Shen X, Yang J, Yuan J, Yang RL, Mao K, Zhao DH and Li CJ: TIMP-1 mediates the inhibitory effect of interleukin-6 on the proliferation of a hepatocarcinoma cell line in a STAT3-dependent manner. Braz J Med Biol Res. 40:621–631. 2007. View Article : Google Scholar : PubMed/NCBI
27	Zhao YD, Li ZY, Sheng WH, Miao J and Yang J: Adenovirus-mediated ING4/IL-24 double tumor suppressor gene co-transfer enhances antitumor activity in human breast cancer cells. Oncol Rep. 28:1315–1324. 2012.PubMed/NCBI
28	Deng WG, Kawashima H, Wu G, Jayachandran G, Xu K, Minna JD, Roth JA and Ji L: Synergistic tumor suppression by coexpression of FUS1 and p53 is associated with down-regulation of murine double minute-2 and activation of the apoptotic protease-activating factor 1-dependent apoptotic pathway in human non-small cell lung cancer cells. Cancer Res. 67:709–717. 2007. View Article : Google Scholar : PubMed/NCBI